Lifecore Biomedical, Inc.

Sep 3, 2026

Lifecore Biomedical to Participate at CPHI Global Conference

Lifecore Biomedical, a contract development and manufacturing organization, will participate in the CPHI Global Conference from October 6-8, 2026, in Milan, Italy. Company leaders will engage with potential clients to discuss their injectable manufacturing services. This event underscores Lifecore's role in the biopharmaceutical sector.

Sep 2, 2026

▲ +8%on this newsshared move

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company

Lifecore Biomedical has signed a significant agreement to support the commercial manufacturing of an injectable drug product for a global pharmaceutical company. This marks the company's seventh late-stage commercial program and is expected to contribute to revenues by 2028. The agreement highlights Lifecore's technical expertise and commitment to expanding its development pipeline.

Aug 5, 2026

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Lifecore Biomedical reported its financial results for the second quarter of 2026, highlighting a decrease in revenue and net loss compared to the previous year. Despite these challenges, the company added 13 new programs to its pipeline and reaffirmed its financial guidance for 2026. Lifecore's ongoing cost reduction efforts aim to enhance productivity and support long-term profitability.

Jul 29, 2026

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Lifecore Biomedical, Inc. will announce its financial results for Q2 2026 on August 5, 2026. The report will be available before market opening, followed by a live webcast at 8:00 a.m. ET. The webcast will also be archived for 30 days on the company's website, highlighting Lifecore's ongoing commitment to transparency and investor engagement.

Jul 28, 2026

Lifecore Biomedical Signs Three New Customer Agreements

Lifecore Biomedical has signed three new customer agreements, enhancing its pipeline of early- and late-stage programs. One agreement focuses on a late-stage development program in regenerative medicine, while the other two involve early-stage projects with a global medical technology company. These agreements are anticipated to contribute to Lifecore's revenue by 2028, reflecting the company's growth strategy.

Jun 29, 2026

Quality to the Core: A Conversation with Patrick Curran

The article features a conversation with Patrick Curran, Warehouse Manager at Lifecore, highlighting the importance of quality management in logistics operations. Lifecore's commitment to quality is evident through their rigorous inventory management and compliance processes. The company prioritizes precision and documentation over speed, ensuring that manufacturing remains uninterrupted by material shortages.

Jun 15, 2026

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Lifecore Biomedical has signed a new agreement with a global pharmaceutical company to support the commercial production of an injectable suspension product for neurological disorders. This agreement marks the seventh addition to Lifecore's late-stage pipeline in just seven months, showcasing the company's growing momentum and expertise in specialized manufacturing. CEO Paul Josephs emphasized the confidence in Lifecore's capabilities and the increasing demand for complex pharmaceutical products.

Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer

Lifecore Biomedical has signed a manufacturing services agreement with a prominent ophthalmic disease management provider. This agreement involves process development and technical transfer for a next-generation injectable product. It marks the sixth addition to Lifecore's late-stage pipeline in just seven months, highlighting the company's growth strategy in the ophthalmic injectables sector.

May 27, 2026

Quality to the Core: A Conversation with Jeremy Huotari

The article features an interview with Jeremy Huotari, a Staff Project Manager at Lifecore, discussing the critical role of cleanroom design in pharmaceutical manufacturing. Huotari highlights how quality management is integrated into facility design, emphasizing that every decision impacts product quality and patient safety. His extensive experience provides insights into maintaining cleanrooms while production continues.

May 21, 2026

▲ +9%on this newsshared move

Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference

Lifecore Biomedical, a contract development and manufacturing organization, has announced its participation in the upcoming William Blair 46th Annual Growth Stock Conference. The event is scheduled for June 2-4, 2026, in Chicago, Illinois. Key executives from Lifecore, including CEO Paul Josephs and CFO Ryan Lake, will attend and engage in investor meetings. This participation highlights Lifecore's commitment to attracting investor attention and fostering relationships within the biopharmaceutical sector.

May 13, 2026

Lifecore Biomedical to Participate at CDMO Live Europe

Lifecore Biomedical, Inc. will participate in the upcoming CDMO Live Europe conference scheduled for May 19-21, 2026, in Rotterdam, Netherlands. The company, known for its capabilities in the development and manufacturing of sterile injectable products, invites interested parties to arrange meetings during the event. Lifecore has a strong reputation in the industry, particularly in producing injectable-grade hyaluronic acid.

May 6, 2026

Lifecore Biomedical Reports Financial Results for the First Quarter Ended

Lifecore Biomedical, Inc. announced its financial results for the first quarter ending March 31, 2026, reporting a 34% decrease in revenue compared to the prior year. Despite the revenue drop, the company reaffirmed its 2026 financial guidance, highlighting successful execution of new commercial contracts and cost containment initiatives that led to a 52% reduction in operating expenses. The firm saw its gross profit margin decline to 19% and an increase in net loss year-over-year. Lifecore's conference call will discuss these developments and their strategic outlook.

Apr 29, 2026

Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026

Lifecore Biomedical, Inc. is set to report its financial results for the first quarter of 2026 on May 6, 2026, before market opening. The company's senior management will host a webcast at 8:00 a.m. Eastern Time on that day to discuss the results. Investors and interested parties can access the live and archived webcasts through Lifecore's Investor Events & Presentations page.

Apr 22, 2026

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Biomedical, Inc. announced the grant of a restricted stock unit (RSU) award of 5,000 shares to a newly hired employee as part of its Equity Inducement Plan. This grant, effective April 20, 2026, was approved by the company's compensation committee and serves as an incentive for the employee to join Lifecore. The RSUs will vest on the third anniversary of the grant date, contingent upon continued employment.

Apr 8, 2026

Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit

Lifecore Biomedical, Inc. (LFCR) will participate in the 12th Annual American Biomanufacturing Summit scheduled for April 14-15, 2026, in San Francisco, CA. The company aims to discuss its expertise in process development and manufacturing services for injectable pharmaceutical products. This participation underscores Lifecore's position as a key player in the CDMO sector.

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 26, 2026

Lifecore Biomedical announced the granting of 18,500 restricted stock units (RSUs) to a newly hired employee as part of its Equity Inducement Plan. This award, approved by the compensation committee, is intended to incentivize the new hire's commitment to the company. The RSUs will vest after three years, contingent on continued employment.

Mar 26, 2026

▼ -7.6%on this newsshared move

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

Lifecore Biomedical has signed two new manufacturing agreements with an existing U.S. biopharmaceutical customer. One agreement involves a commercial site transfer for a marketed product, while the other expands manufacturing capabilities to a new delivery system. These agreements are expected to enhance Lifecore's revenue potential by 2028 and reflect the company's successful commercial strategy.

Mar 23, 2026

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

Lifecore Biomedical has entered into a commercial manufacturing agreement with a leading aesthetics company for an established product. This marks the third such agreement in five months, reflecting the company's strategic focus on late-stage programs. The partnership is anticipated to generate revenue within 24 months, contributing to Lifecore's projected growth through 2029.

Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended

Lifecore Biomedical reported strong financial results for the fourth quarter and transition period ending December 31, 2025, with revenues reaching $35.7 million and an overall growth of 20% year-over-year. The company signed five new programs during this period, highlighting its expansion efforts. Although the company projects significant revenue growth for 2026, it also anticipates a net loss and faces risks from customer changes and delays in product launches. Lifecore aims for continued improvement in EBITDA margins and revenue growth through strategic initiatives and customer diversification.

Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLP is investigating Lifecore Biomedical on behalf of its investors following a report of significant losses. The company's Q4 2025 financial results revealed a projected revenue drop to between $120 million and $125 million, compared to $141.4 million in the previous year. This decline has been driven by operational issues such as customer loss and delays in product launches, leading to an 18% stock price drop. Investors impacted by these events are encouraged to reach out to Johnson Fistel for potential recovery of losses.

Mar 10, 2026

Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum

Lifecore Biomedical, Inc. will participate in the 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum scheduled for March 17-18, 2026. Mr. Josephs, a key figure at Lifecore, will be a featured speaker in a fireside chat, offering insights into the company's operations. Additionally, Lifecore management will engage in investor meetings during the event. This forum serves as a platform for Lifecore to connect with potential investors and highlight its expertise in injectable pharmaceutical products.

Mar 9, 2026

Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026

Lifecore Biomedical, Inc. has announced it will report its financial results for the fourth quarter and transition period ended December 31, 2025, on March 16, 2026. The report will be available before market opening, followed by a webcast at 8:30 a.m. Eastern Time featuring senior management discussing the results. The archived version of the webcast will be accessible on Lifecore's website for 30 days, emphasizing the company's commitment to communication with stakeholders.

Mar 5, 2026

LFCRPhases

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment

Lifecore Biomedical has signed a new agreement with Indomo to support the development of DT-001, a corticosteroid drug for treating inflammatory acne. Lifecore will manufacture clinical batches of the drug to facilitate its advancement into Phase 2 clinical trials scheduled for 2026. The partnership aims to enhance patient access to effective acne treatments through the innovative ClearPen device.

Feb 17, 2026

Lifecore Biomedical to Participate at DCAT Week 2026

Lifecore Biomedical, a contract development and manufacturing organization, will participate in DCAT Week 2026, scheduled for March 23-26 in New York City. The event provides an opportunity for Lifecore to connect with industry professionals and showcase its capabilities in sterile injectable products. The company emphasizes its extensive experience in supporting biopharmaceutical innovations.

Jan 19, 2026

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026

Lifecore Biomedical, Inc. announced the approval of inducement grants under Nasdaq Listing Rule 5635(c)(4) for two newly hired employees. The grants include restricted stock units and stock options, aimed at incentivizing talent acquisition. The RSUs will vest after three years, while the stock options have a structured vesting schedule over seven years.

Jan 16, 2026

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Lifecore Biomedical, Inc. announced the approval of equity inducement grants for two newly hired employees under its Equity Inducement Plan. The grants include restricted stock units and stock options totaling 10,513 shares, which will vest over time, subject to employment continuity. This initiative reflects Lifecore's growth strategy and commitment to attract talent while adhering to Nasdaq regulations.

Dec 18, 2025

Lifecore Biomedical to be Added to Nasdaq Biotech Index

Lifecore Biomedical, Inc. has been notified by Nasdaq of its inclusion in the Nasdaq Biotech Index, effective December 22, 2025. This announcement reflects the company's compliance with eligibility criteria such as market capitalization and trading volume. Lifecore is recognized for its expertise in contract development and manufacturing, particularly in sterile injectable pharmaceutical products. The Nasdaq Biotech Index aims to track the performance of significant biotechnology and pharmaceutical companies listed on Nasdaq.

Dec 17, 2025

▲ +9.9%on this newsshared move

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

Lifecore Biomedical has signed a CDMO master services agreement with a new large multinational pharmaceutical customer. This agreement involves development services and tech transfer for an injectable product, aiming to transition commercial supply to Lifecore's facilities. The new partner has the potential to become one of Lifecore's top five customers, highlighting the company's growing business momentum.

Dec 16, 2025

Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference

Lifecore Biomedical, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12-15, 2026, in San Francisco. As a contract development and manufacturing organization, Lifecore specializes in sterile injectable products and has over 40 years of industry experience. This participation highlights the company's commitment to innovation in biopharmaceuticals.

Nov 11, 2025

▲ +6.2%on this news

Lifecore Biomedical to Participate in Upcoming Investor Conferences

Lifecore Biomedical, Inc. will participate in two investor conferences from November 17-20, 2025. CEO Paul Josephs will present a corporate overview and engage in investor meetings in London, followed by a fireside chat in Nashville. Webcasts of these events will be available on Lifecore's investor website.

Nov 6, 2025

Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update

Lifecore Biomedical reported a 26% increase in revenue for the three months ended September 30, 2025, totaling $31.1 million. The company highlighted improvements in efficiency and productivity, along with a positive outlook for future growth. However, it also reported a net loss of $10 million, attributed to increased interest expenses and lower development revenue. Lifecore aims for a revenue CAGR of over 12% and improved EBITDA margins in the coming years.

Oct 30, 2025

Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025

Lifecore Biomedical, Inc. will report its financial results for the three months ended September 30, 2025, on November 6, 2025, after market close. A webcast is scheduled for that day at 4:30 p.m. Eastern Time, where the management team will discuss the results. Lifecore specializes in contract development and manufacturing for sterile injectable products and boasts over 40 years of experience in this sector.

Oct 29, 2025

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

Lifecore Biomedical has been selected as the new commercial manufacturing partner for a leading global pharmaceutical company, marking its second agreement with this organization in recent months. This site transfer will enhance Lifecore's capacity and broaden its customer base. Additionally, Lifecore signed a pre-clinical formulation development agreement with an early-stage biotech firm, further expanding its growth pipeline.

Oct 28, 2025

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market

Lifecore Biomedical and PolyPeptide Laboratories have announced a collaboration to provide an integrated solution for peptide-based pharmaceuticals in the U.S. This partnership aims to enhance the manufacturing process by combining Lifecore's expertise in formulation and packaging with PolyPeptide's manufacturing capabilities. The goal is to reduce development costs and risks while ensuring regulatory compliance.

Oct 13, 2025

Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events

Lifecore Biomedical, Inc. has announced its participation in three upcoming industry events. The company, known for its expertise in contract development and manufacturing, aims to connect with potential partners and showcase its capabilities in sterile injectable products. This engagement highlights Lifecore's commitment to the biopharmaceutical sector.

Oct 1, 2025

LIFECORE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Lifecore Biomedical, Inc. and Encourages Long-Term Investors to Contact the Firm – LFCR

Kaskela Law LLC has announced an investigation into Lifecore Biomedical, Inc. for potential breach of fiduciary duty claims. This comes in light of a securities fraud complaint alleging that Lifecore's executives failed to disclose significant internal control deficiencies, leading to material misstatements in financial reporting. Following disclosures about these issues, Lifecore's stock saw a notable decrease in value. The investigation will examine whether the company's board violated securities laws or their fiduciary duties.

Sep 27, 2025

LIFECORE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating LifeCore Biomedical, Inc. on behalf of long-term stockholders following a class action complaint that alleges the company made false and misleading statements about its business and operations. The investigation focuses on potential breaches of fiduciary duties by the board of directors. Key allegations include deficiencies in internal financial controls, ineffective remediation efforts, and inaccurate financial statements that may have misled investors. Long-term stockholders are encouraged to contact the law firm for further information regarding their rights and potential claims.

Sep 4, 2025

▼ -5.2%on this news

Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference

Lifecore Biomedical will participate as a Gold Sponsor at the 24th Annual Contract Pharma Contracting and Outsourcing Conference on September 18-19, 2025. The event is significant for pharmaceutical outsourcing and contract manufacturing. Lifecore aims to showcase its injectables development expertise and engage with potential customers. The company is focused on expanding its growth strategy and enhancing its market presence.

Aug 15, 2025

LIFECORE ALERT: Bragar Eagel & Squire, P.C. is Investigating LifeCore Biomedical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

LifeCore Biomedical, Inc. is under investigation by Bragar Eagel & Squire, P.C. on behalf of long-term stockholders due to a class action complaint filed on July 29, 2024. The complaint alleges that the company made materially false and misleading statements about its financial conditions and operations during the class period from October 7, 2020, to March 19, 2024. Concerns raised include deficient internal controls over financial reporting and the ineffective remediation efforts afterward. Affected investors are encouraged to contact the law firm for further assistance regarding their rights.

Aug 12, 2025